Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque healthcare fraud we have encountered, not only for its ...

The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics. Scorpion stated in its report, "TransMedics is the most extreme and grotesque ...

This should act as a reminder of the risks the industry faces. We sell different types of products and services to both investment professionals and individual investors. These products and ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The investment firm alleges fraudulent practices at TransMedics, describing it as ...

TransMedics Group's management had not responded publicly to Scorpion Capital's report at the time of this writing. Some of Scorpion's allegations might seem questionable to anyone who has ...

Investing.com -- Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including ...